A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma

A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma

Abstract Background Cytoreductive nephrectomy is thought to improve survival in metastatic renal cell carcinoma (mRCC). As many patients are ineligible for major surgery, we hypothesized that SABR could be a safe alternative. Methods In this dose-escalation trial, inoperable mRCC patients underwent...

Full description

Bibliographic Details
Main Authors: Rohann J. M. Correa, Belal Ahmad, Andrew Warner, Craig Johnson, Mary J. MacKenzie, Stephen E. Pautler, Glenn S. Bauman, George B. Rodrigues, Alexander V. Louie
Format: Article
Language:English
Published: BMC 2018-03-01
Series:Radiation Oncology
Subjects:
Primary tumour
Renal cell
Metastatic
Stereotactic ablative radiotherapy
Online Access:http://link.springer.com/article/10.1186/s13014-018-0992-3

Internet

http://link.springer.com/article/10.1186/s13014-018-0992-3

Similar Items